Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Surface Oncology Inc (SURF)

Surface Oncology Inc (SURF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 302,266
  • Shares Outstanding, K 43,429
  • Annual Sales, $ 126,160 K
  • Annual Income, $ 59,340 K
  • 60-Month Beta 1.86
  • Price/Sales 2.39
  • Price/Cash Flow 4.63
  • Price/Book 2.00
Trade SURF with:

Options Overview

Details
  • Implied Volatility 96.98%
  • Historical Volatility 55.00%
  • IV Percentile 1%
  • IV Rank 3.84%
  • IV High 249.58% on 08/28/20
  • IV Low 90.89% on 06/21/21
  • Put/Call Vol Ratio 0.16
  • Today's Volume 910
  • Volume Avg (30-Day) 1,908
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 17,028
  • Open Int (30-Day) 26,298

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.34
  • Number of Estimates 4
  • High Estimate -0.14
  • Low Estimate -0.42
  • Prior Year -0.44
  • Growth Rate Est. (year over year) +22.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.84 +7.75%
on 06/22/21
9.57 -22.99%
on 06/03/21
-1.35 (-15.48%)
since 05/21/21
3-Month
6.26 +17.73%
on 04/20/21
9.57 -22.99%
on 06/03/21
-1.33 (-15.29%)
since 03/23/21
52-Week
4.73 +55.81%
on 07/13/20
14.40 -48.82%
on 01/21/21
+2.28 (+44.79%)
since 06/23/20

Most Recent Stories

More News
Thinking about buying stock in Windtree Therapeutics, Coherus Biosciences, Surface Oncology, Energous Corp, or Nokia?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WINT, CHRS, SURF, WATT, and NOK.

CHRS : 14.64 (-2.85%)
SURF : 7.37 (+5.89%)
WINT : 2.24 (+5.16%)
WATT : 2.96 (+6.86%)
NOK : 5.05 (-1.17%)
Surface Oncology to Collaborate with Roche on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, as Part of a Novel Combination in Patients with Advanced Treatment-naive Hepatocellular Carcinoma

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced a clinical trial collaboration...

SURF : 7.37 (+5.89%)
Implied Volatility Surging for Surface Oncology (SURF) Stock Options

Investors need to pay close attention to Surface Oncology (SURF) stock based on the movements in the options market lately.

SURF : 7.37 (+5.89%)
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2021

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate...

SURF : 7.37 (+5.89%)
Surface Oncology Expands Leadership Team with Key Executive Appointment and Promotions

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today the appointment of Henry Rath...

SURF : 7.37 (+5.89%)
Surface Oncology Presents Promising Preclinical Data for Lead Immunotherapy Product Candidates at the American Association for Cancer Research Annual Meeting

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, will present preclinical findings supporting...

SURF : 7.37 (+5.89%)
Thinking about buying stock in Arcadia Biosciences, Ocugen, Broadwind, Surface Oncology, or Lineage Cell Therapeutics?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RKDA, OCGN, BWEN, SURF, and LCTX.

LCTX : 2.79 (+1.82%)
OCGN : 7.56 (+2.02%)
SURF : 7.37 (+5.89%)
BWEN : 4.89 (+6.77%)
RKDA : 2.92 (+1.74%)
Surface Oncology's SRF617 Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug...

SURF : 7.37 (+5.89%)
Thinking about buying stock in AstraZeneca, Pfizer, Surface Oncology, Intel Corp, or Charles Schwab?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AZN, PFE, SURF, INTC, and SCHW.

SURF : 7.37 (+5.89%)
AZN : 57.98 (+0.16%)
INTC : 55.26 (-1.09%)
PFE : 39.05 (-1.41%)
SCHW : 72.89 (+0.54%)
Surface Oncology to Present Preclinical Data for Lead Product Programs at the American Association for Cancer Research Annual Meeting

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced two scientific e-posters sharing...

SURF : 7.37 (+5.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Surface Oncology, Inc. is a clinical-stage immuno-oncology company. It develops therapies for the treatment of cancer. The company's product pipeline includes CD47, CD73, SRF231, SRF373, SRF617, SRF388 and SRF231 which are in clinical stage. Surface Oncology is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 7.84
2nd Resistance Point 7.62
1st Resistance Point 7.49
Last Price 7.37
1st Support Level 7.14
2nd Support Level 6.92
3rd Support Level 6.79

See More

52-Week High 14.40
Fibonacci 61.8% 10.71
Fibonacci 50% 9.56
Fibonacci 38.2% 8.42
Last Price 7.37
52-Week Low 4.73

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar